Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 206 articles:
HTML format



Single Articles


    January 2025
  1. KANG SJ, Park J, Choi GS, Kim JG, et al
    Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.
    PLoS One. 2025;20:e0313438.
    PubMed     Abstract available


  2. MAMUDU L, Sulley S, Atandoh PH, Reyes JL, et al
    Disparities in time to treatment initiation of invasive lung cancer among Black and White patients in Tennessee.
    PLoS One. 2025;20:e0311186.
    PubMed     Abstract available


  3. CHEN X, Kanhar GM, Hu S, Wu C, et al
    Occult metastases and survival of lung cancer by clinical diagnosis and CT screening: A simulation study.
    PLoS One. 2025;20:e0313544.
    PubMed     Abstract available


  4. HUANG T, Ma K, Wang Y
    Characterization and evaluation of the cytotoxic, antioxidant, and anti-human lung cancer properties of copper nanoparticles green-synthesized by fennel extract following the PI3K/AKT/Mtor signaling pathway.
    PLoS One. 2025;20:e0309207.
    PubMed     Abstract available


  5. SOBOLEVA A, Kaznatcheev A, Cavill R, Schneider K, et al
    Validation of polymorphic Gompertzian model of cancer through in vitro and in vivo data.
    PLoS One. 2025;20:e0310844.
    PubMed     Abstract available


  6. SULLIVAN FM, Mair FS, Anderson W, Chew C, et al
    Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.
    PLoS One. 2025;20:e0306163.
    PubMed     Abstract available


  7. GWON HR, Woo A, Yong SH, Park YM, et al
    Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm.
    PLoS One. 2025;20:e0315898.
    PubMed     Abstract available


  8. ABDULLAH S, Altwaijry N, Alnakhli M, ALenezi G, et al
    Novel methotrexate long-acting system using ambroxol coating and hydroxypropyl methylcellulose encapsulation for preferential and enhanced lung cancer efficiency.
    PLoS One. 2025;20:e0314941.
    PubMed     Abstract available


  9. ANOSOVA O, Head A, Collins B, Alexiou A, et al
    Estimating the burden of underdiagnosis within England: A modelling study of linked primary care data.
    PLoS One. 2025;20:e0313877.
    PubMed     Abstract available


  10. AFZAL M, Abusalah MAHA, Shehzadi N, Absar M, et al
    Investigation of biometabolites and novel antimicrobial peptides derived from promising source Cordyceps militaris and effect of non-small cell lung cancer genes computationally.
    PLoS One. 2025;20:e0310103.
    PubMed     Abstract available


  11. ZAPATA DONGO RJ, Fontana D, Mologni L, Faya Castillo JE, et al
    Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer.
    PLoS One. 2025;20:e0308747.
    PubMed     Abstract available


  12. WANG Q, Luo Y, Zhao Y, Wang S, et al
    Automated recognition and segmentation of lung cancer cytological images based on deep learning.
    PLoS One. 2025;20:e0317996.
    PubMed     Abstract available


  13. JAHAN F, Haque S, Hogg J, Price A, et al
    Assessing the influence of the modifiable areal unit problem on Bayesian disease mapping in Queensland, Australia.
    PLoS One. 2025;20:e0313079.
    PubMed     Abstract available


  14. PRAKAIKIETIKUL P, Tajarenmuang P, Losuriya P, Ina N, et al
    Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.
    PLoS One. 2025;20:e0313577.
    PubMed     Abstract available


  15. ZHU Q, Fei L
    Cross-ViT based benign and malignant classification of pulmonary nodules.
    PLoS One. 2025;20:e0318670.
    PubMed     Abstract available


  16. SHAO K, Du F, Qiu L, Zhang Y, et al
    Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.
    PLoS One. 2025;20:e0318462.
    PubMed     Abstract available


  17. BARBEAU LMO, Beelen NA, Savelkouls KG, Keulers TGH, et al
    MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0316716.
    PubMed     Abstract available


  18. RABBY MS, Islam MM, Kumar S, Maniruzzaman M, et al
    Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches.
    PLoS One. 2025;20:e0317296.
    PubMed     Abstract available


  19. KHAN MA, Khan ZA, Husain I, Upadhyay S, et al
    Effects of pressure on the survival and viability of cancer cells in vitro: An analytical study.
    PLoS One. 2025;20:e0311685.
    PubMed     Abstract available


  20. HIGASHI S, Yamakuchi M, Hashinokuchi H, Takenouchi K, et al
    Adaptation to acidic conditions that mimic the tumor microenvironment, downregulates miR-193b-3p, and induces EMT via TGFbeta2 in A549 cells.
    PLoS One. 2025;20:e0318811.
    PubMed     Abstract available


  21. DIAO S, Wan Y, Huang D, Huang S, et al
    Optimizing Bi-LSTM networks for improved lung cancer detection accuracy.
    PLoS One. 2025;20:e0316136.
    PubMed     Abstract available


  22. PAN X, Togka K, Ten Berge H, de Jong L, et al
    Lung cancer screening with volume computed tomography is cost-effective in Greece.
    PLoS One. 2025;20:e0316351.
    PubMed     Abstract available


  23. GHIROTTO L, Paci E, Bricci C, Marini S, et al
    Self-blaming as a barrier to lung cancer screening and smoking cessation programs in Italy. A qualitative study.
    PLoS One. 2025;20:e0318732.
    PubMed     Abstract available



  24. Retraction: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer.
    PLoS One. 2025;20:e0320171.
    PubMed    


  25. TANG S, Bao Q, Ji Q, Wang T, et al
    Improvement of RT-DETR model for ground glass pulmonary nodule detection.
    PLoS One. 2025;20:e0317114.
    PubMed     Abstract available


  26. ALLEN J, Healey G, Macdonald I
    Lung cancer associated autoantibody responses are detectable years before clinical presentation.
    PLoS One. 2025;20:e0315220.
    PubMed     Abstract available


  27. LV Z, Liu P, Yang Y, Ji J, et al
    Correction: (-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2alpha/ATF4 signaling pathway.
    PLoS One. 2025;20:e0320174.
    PubMed     Abstract available


  28. HOSSAIN MS, Basak N, Mollah MA, Nahiduzzaman M, et al
    Ensemble-based multiclass lung cancer classification using hybrid CNN-SVD feature extraction and selection method.
    PLoS One. 2025;20:e0318219.
    PubMed     Abstract available


  29. LI C, Zhong S, Chen J, Mu X, et al
    TsRNA-49-73-Glu-CTC: A promising serum biomarker in non-small cell lung cancer.
    PLoS One. 2025;20:e0320187.
    PubMed     Abstract available


  30. ZHANG DT, Shi GX, Jia JY, Tan FW, et al
    Electroacupuncture for acute postoperative pain during coughing after video-assisted thoracoscopic surgery: study protocol for a pilot randomized controlled trial.
    PLoS One. 2025;20:e0316698.
    PubMed     Abstract available


  31. ZHENG Z, Zhu H, Fang L
    Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A cost-effectiveness analysis.
    PLoS One. 2025;20:e0320189.
    PubMed     Abstract available



  32. Correction: Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.
    PLoS One. 2025;20:e0321150.
    PubMed     Abstract available


  33. JAVRUSHYAN H, Ginovyan M, Harutyunyan T, Gevorgyan S, et al
    Elucidating the impact of Hypericum alpestre extract and L-NAME on the PI3K/Akt signaling pathway in A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cells.
    PLoS One. 2025;20:e0303736.
    PubMed     Abstract available


  34. WANG M, Jiang W, Wei T, Li Z, et al
    Dynamic changes and metabolic function of intestinal flora in patients with postoperative pneumonia after lung cancer surgery.
    PLoS One. 2025;20:e0321016.
    PubMed     Abstract available


  35. KIM MS, Kim MS
    Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells.
    PLoS One. 2025;20:e0320668.
    PubMed     Abstract available


  36. HAO L, Zhang J, Di Y, Qi Z, et al
    Predicting a failure of postoperative thromboprophylaxis in non-small cell lung cancer: A stacking machine learning approach.
    PLoS One. 2025;20:e0320674.
    PubMed     Abstract available


  37. EL-TANANI M, Satyam SM, Rabbani SA, Obeidat RM, et al
    Decoding oncogenic secrets of regulator of chromosome condensation 1: A breakthrough mechanistic evidence from breast and lung cancer models.
    PLoS One. 2025;20:e0319748.
    PubMed     Abstract available


  38. PRAKAIKIETIKUL P, Wannasopha Y, Euathrongchit J, Tantraworasin A, et al
    CT features and histogram analysis of non-contrast images for differentiating malignant and benign mediastinal lymph nodes in Non-Small Cell Lung Cancer (NSCLC).
    PLoS One. 2025;20:e0321921.
    PubMed     Abstract available


  39. GAO C, Liu M, Sun Y, Zhao Z, et al
    Association between advanced lung cancer inflammation index and gallstone prevalence among U.S. adults: A population-based study.
    PLoS One. 2025;20:e0321733.
    PubMed     Abstract available


  40. KUO P, Elboudwarej E, Zavodovskaya M, Lin KW, et al
    Trop-2 expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0321555.
    PubMed     Abstract available


  41. PONGPIACHAN S, Tipmanee D, Khumsup C, Hirunyatrakul P, et al
    Size-segregated analysis of PAHs in Urban air: Source apportionment and health risk assessment in an Urban canal-adjacent environment.
    PLoS One. 2025;20:e0320405.
    PubMed     Abstract available


  42. MALIK V, Mittal R, Gupta D, Juneja S, et al
    Optimizing chemotherapeutic targets in non-small cell lung cancer with transfer learning for precision medicine.
    PLoS One. 2025;20:e0319499.
    PubMed     Abstract available


  43. YU W, Long L, Hou Q, Yi B, et al
    Development of a nomogram for overall survival prediction in primary upper lobe lung cancer patients: A SEER population-based analysis.
    PLoS One. 2025;20:e0321955.
    PubMed     Abstract available


  44. MOUSAVI SF, Masoudi S, Rezaei N, Pourghazi F, et al
    Survival assessment and pre-diagnostic risk factors for lung cancer incidence: Insights from the Golestan Cohort Study.
    PLoS One. 2025;20:e0320931.
    PubMed     Abstract available


  45. DE-TORRES JP, Giron-Flamenco JJ, Rodriguez M, de la Fuente-Ano A, et al
    Exploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program.
    PLoS One. 2025;20:e0320704.
    PubMed     Abstract available


  46. OTERO-CARRASCO B, Nevado PT, Munoz RA, Ferreiro GD, et al
    Finding patterns in lung cancer protein sequences for drug repurposing.
    PLoS One. 2025;20:e0322546.
    PubMed     Abstract available


  47. RAO S, Wu H, Zhang G, Dong W, et al
    A comparative analysis of the burden, trends and inequalities of tracheal, bronchus, and lung cancer in India from 2000 to 2021: A systematic analysis for the Global Burden of Disease study 2021.
    PLoS One. 2025;20:e0322646.
    PubMed     Abstract available


  48. SALOMONSSON A, Ehinger D, Jonsson M, Botling J, et al
    Gene expression-based identification of prognostic markers in lung adenocarcinoma.
    PLoS One. 2025;20:e0310232.
    PubMed     Abstract available


  49. LI Z, Zhu Z, Wang P, Hou C, et al
    Diagnostic, prognostic, and immunological roles of FUT8 in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2025;20:e0321756.
    PubMed     Abstract available


  50. YIN X, Liang HW, Liu Y, Huang W, et al
    Lobectomy versus sublobar resection on survival in patients with stage T1-2N0M0 small cell lung cancer.
    PLoS One. 2025;20:e0324315.
    PubMed     Abstract available



  51. Retraction: Efficient lung cancer detection using computational intelligence and ensemble learning.
    PLoS One. 2025;20:e0324356.
    PubMed    


  52. PHILIBERT R, Beach SRH, Mills JA, Dawes K, et al
    Epigenetic assessments of alcohol consumption predict mortality in smokers at risk for lung cancer in the prostate, lung, colorectal and ovarian cancer screening trial.
    PLoS One. 2025;20:e0322783.
    PubMed     Abstract available


  53. PEREZ AL, Zamora M, Bahena M, Aramburo-Williams R, et al
    The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability.
    PLoS One. 2025;20:e0316983.
    PubMed     Abstract available


  54. ZHANG Y, Hu Y, Xi J, Wu B, et al
    Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.
    PLoS One. 2025;20:e0319357.
    PubMed     Abstract available


  55. JIM JR, Rayed ME, Mridha MF, Nur K, et al
    XLLC-Net: A lightweight and explainable CNN for accurate lung cancer classification using histopathological images.
    PLoS One. 2025;20:e0322488.
    PubMed     Abstract available


  56. ZHENG Z, Zhu H, Fang L
    Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
    PLoS One. 2025;20:e0325171.
    PubMed     Abstract available


  57. WANG X, Sharpnack J, Lee TCM
    Improving lung cancer diagnosis and survival prediction with deep learning and CT imaging.
    PLoS One. 2025;20:e0323174.
    PubMed     Abstract available


  58. ABUMANSOUR H, Abusara OH, Abu-Sini M, Khalil W, et al
    Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells.
    PLoS One. 2025;20:e0324930.
    PubMed     Abstract available


    January 2024
  59. ZHANG J, Huang X, Liu Y, Han Y, et al
    GAN-based medical image small region forgery detection via a two-stage cascade framework.
    PLoS One. 2024;19:e0290303.
    PubMed     Abstract available


  60. GAO X, Tang M, Tian S, Li J, et al
    ncRNAs-mediated TIMELESS overexpression in lung adenocarcinoma correlates with reduced tumor immune cell infiltration and poor prognosis.
    PLoS One. 2024;19:e0296829.
    PubMed     Abstract available



  61. Expression of Concern: Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer.
    PLoS One. 2024;19:e0298436.
    PubMed    


  62. KANG J, Zhang J, Tian Z, Xu Y, et al
    The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
    PLoS One. 2024;19:e0276318.
    PubMed     Abstract available


  63. FAYA CASTILLO JE, Zapata Dongo RJ, Wong Chero PA, Infante Varillas SF, et al
    Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
    PLoS One. 2024;19:e0295966.
    PubMed     Abstract available



  64. Expression of Concern: Comparison of 18F-FDG PET/CT and DWI for detection of mediastinal nodal metastasis in non-small cell lung cancer: A meta-analysis.
    PLoS One. 2024;19:e0299045.
    PubMed    


  65. TIAN P, Du D, Yang L, Zhou N, et al
    SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.
    PLoS One. 2024;19:e0298295.
    PubMed     Abstract available


  66. CHEN Q, Li W, Cai N, Chen W, et al
    Comparison of postoperative complications in mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: Protocol for a systematic review and meta-analysis.
    PLoS One. 2024;19:e0298368.
    PubMed     Abstract available


  67. MORI S, Ueki Y, Hasegawa M, Nakamura K, et al
    Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
    PLoS One. 2024;19:e0298573.
    PubMed     Abstract available


  68. WANG H, Tang H, Yuan S, Liang C, et al
    IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells.
    PLoS One. 2024;19:e0299028.
    PubMed     Abstract available


  69. YOO SJ, Park YS, Choi H, Kim DS, et al
    Prospective evaluation of deep learning image reconstruction for Lung-RADS and automatic nodule volumetry on ultralow-dose chest CT.
    PLoS One. 2024;19:e0297390.
    PubMed     Abstract available


  70. AJENU EO, Seideneck AM, Pandellapalli E, Shinsky EM, et al
    ABCG2 transporter reduces protein aggregation in cigarette smoke condensate-exposed A549 lung cancer cells.
    PLoS One. 2024;19:e0297661.
    PubMed     Abstract available


  71. KESSLER LG, Comstock B, Aiello Bowles EJ, Mou J, et al
    Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design.
    PLoS One. 2024;19:e0297773.
    PubMed     Abstract available


  72. AHMAD A, Kulachi MO, Farman M, Junjua MU, et al
    Mathematical modeling and control of lung cancer with IL2 cytokine and anti-PD-L1 inhibitor effects for low immune individuals.
    PLoS One. 2024;19:e0299560.
    PubMed     Abstract available


  73. LEE YJ, Kang N, Nam J, Lee EG, et al
    The preventative effects of statin on lung cancer development in patients with idiopathic pulmonary fibrosis using the National Health Insurance Service Database in Korea.
    PLoS One. 2024;19:e0299484.
    PubMed     Abstract available


  74. MALIK H, Anees T
    Multi-modal deep learning methods for classification of chest diseases using different medical imaging and cough sounds.
    PLoS One. 2024;19:e0296352.
    PubMed     Abstract available


  75. XUE Y, Zhang D, Jia L, Yang W, et al
    Integrating image and gene-data with a semi-supervised attention model for prediction of KRAS gene mutation status in non-small cell lung cancer.
    PLoS One. 2024;19:e0297331.
    PubMed     Abstract available


  76. MAJUMDER S, Gautam N, Basu A, Sau A, et al
    MENet: A Mitscherlich function based ensemble of CNN models to classify lung cancer using CT scans.
    PLoS One. 2024;19:e0298527.
    PubMed     Abstract available


  77. ZHANG L, Xu L, Chen Z, You H, et al
    Risk factors and related miRNA phenotypes of chronic pain after thoracoscopic surgery in lung adenocarcinoma patients.
    PLoS One. 2024;19:e0297742.
    PubMed     Abstract available


  78. LI Q, Wei Z, Zhang Y, Zheng C, et al
    Causal role of metabolites in non-small cell lung cancer: Mendelian randomization (MR) study.
    PLoS One. 2024;19:e0300904.
    PubMed     Abstract available


  79. MOMOKI Y, Ichinose A, Nakamura K, Iwano S, et al
    Development of automatic generation system for lung nodule finding descriptions.
    PLoS One. 2024;19:e0300325.
    PubMed     Abstract available


  80. HAN H, Huang H, Chen AP, Tang Y, et al
    High CASC expression predicts poor prognosis of lung cancer: A systematic review with meta-analysis.
    PLoS One. 2024;19:e0292726.
    PubMed     Abstract available


  81. ZHANG Y, Liu H, Chang C, Yin Y, et al
    Machine learning for differentiating lung squamous cell cancer from adenocarcinoma using Clinical-Metabolic characteristics and 18F-FDG PET/CT radiomics.
    PLoS One. 2024;19:e0300170.
    PubMed     Abstract available


  82. LV M, Li X, Yin Z, Yang H, et al
    Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
    PLoS One. 2024;19:e0294227.
    PubMed     Abstract available


  83. LE ROUX O, Everitt JI, Counter CM
    p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
    PLoS One. 2024;19:e0292189.
    PubMed     Abstract available


  84. TRIPLETTE M, Kross EK, Snidarich M, Shahrir S, et al
    An alternating-intervention pilot trial on the impact of an informational handout on patient-reported outcomes and follow-up after lung cancer screening.
    PLoS One. 2024;19:e0300352.
    PubMed     Abstract available


  85. MAY T, Clement MS, Halait H, Kohlmann A, et al
    Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.
    PLoS One. 2024;19:e0295987.
    PubMed     Abstract available


  86. ZHANG H, Cheng X, Guo W, Zheng C, et al
    Metastasis patterns and prognosis in young gastric cancer patients: A propensity score?matched SEER database analysis.
    PLoS One. 2024;19:e0301834.
    PubMed     Abstract available


  87. RADWAN AA, Alanazi F, Al-Dhfyan A
    Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation.
    PLoS One. 2024;19:e0298326.
    PubMed     Abstract available


  88. LI H, Huntington S, Gross C, Wang SY, et al
    Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
    PLoS One. 2024;19:e0300789.
    PubMed     Abstract available


  89. ZHANG MS, Yeh YC, Huang HN, Lin LW, et al
    The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
    PLoS One. 2024;19:e0301120.
    PubMed     Abstract available


  90. KONG Y, Hong L, Xu XC, Chen YF, et al
    The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
    PLoS One. 2024;19:e0301931.
    PubMed     Abstract available


  91. WU B, Zhang X, Feng N, Hu Z, et al
    Treatment strategies for stage IA non-small cell lung cancer: A SEER-based population study.
    PLoS One. 2024;19:e0298470.
    PubMed     Abstract available


  92. HUH Y, Sohn YJ, Kim HR, Chun H, et al
    Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea.
    PLoS One. 2024;19:e0300389.
    PubMed     Abstract available


  93. BAK SH, Park J, Lee S, Kim JH, et al
    Clinical usability of 3D gradient-echo-based ultrashort echo time imaging: Is it enough to facilitate diagnostic decision in real-world practice?
    PLoS One. 2024;19:e0296696.
    PubMed     Abstract available


  94. HAN KT, Kim S
    Does improved nurse staffing impact patient outcomes in cancer? Association between chronic diseases and mortality among older adult patients with lung cancer in Korea.
    PLoS One. 2024;19:e0301010.
    PubMed     Abstract available


  95. THU YM, Suzawa K, Tomida S, Ochi K, et al
    PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
    PLoS One. 2024;19:e0300644.
    PubMed     Abstract available


  96. CHANG GC, Shih JY, Yu CJ, Chao HS, et al
    Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
    PLoS One. 2024;19:e0303046.
    PubMed     Abstract available


  97. LEE ACH, Madariaga MLL, Lee SM, Ferguson MK, et al
    The risk analysis index is an independent predictor of outcomes after lung cancer resection.
    PLoS One. 2024;19:e0303281.
    PubMed     Abstract available


  98. WANG H, Zhu H, Ding L, Yang K, et al
    Attention pyramid pooling network for artificial diagnosis on pulmonary nodules.
    PLoS One. 2024;19:e0302641.
    PubMed     Abstract available


  99. N KACHOUIE N, Deebani W, Shutaywi M, Christiani DC, et al
    Lung cancer clustering by identification of similarities and discrepancies of DNA copy numbers using maximal information coefficient.
    PLoS One. 2024;19:e0301131.
    PubMed     Abstract available



  100. Editorial Note: Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of beta-Catenin Signaling.
    PLoS One. 2024;19:e0303600.
    PubMed    


  101. BIANCHI F, Le Noci V, Bernardo G, Gagliano N, et al
    Cigarette smoke sustains immunosuppressive microenvironment inducing M2 macrophage polarization and viability in lung cancer settings.
    PLoS One. 2024;19:e0303875.
    PubMed     Abstract available


  102. LUO W, Chang G, Lin D, Xie H, et al
    3,3'-((3,4,5-trifluoropHenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) inhibit lung cancer cell proliferation and migration.
    PLoS One. 2024;19:e0303186.
    PubMed     Abstract available


  103. ZHONG J, Hua Y, Zou S, Wang B, et al
    Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway.
    PLoS One. 2024;19:e0299921.
    PubMed     Abstract available


  104. BOUKANSA S, Mouhrach I, El Agy F, El Bardai S, et al
    Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report.
    PLoS One. 2024;19:e0298721.
    PubMed     Abstract available


  105. PATHAN RK, Shorna IJ, Hossain MS, Khandaker MU, et al
    The efficacy of machine learning models in lung cancer risk prediction with explainability.
    PLoS One. 2024;19:e0305035.
    PubMed     Abstract available


  106. CUI R, Li Y, Yu X, Wei C, et al
    Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.
    PLoS One. 2024;19:e0304941.
    PubMed     Abstract available


  107. ALSHEHRI MA, Asiri SA, Helmi N, Baeissa HM, et al
    Unrevealing the multitargeted potency of 3-1-BCMIYPPA against lung cancer structural maintenance and suppression proteins through pharmacokinetics, QM-DFT, and multiscale MD simulation studies.
    PLoS One. 2024;19:e0303784.
    PubMed     Abstract available


  108. YU H, Wang Y, Yue X, Zhang H, et al
    Influence of the atmospheric environment on spatial variation of lung cancer incidence in China.
    PLoS One. 2024;19:e0305345.
    PubMed     Abstract available


  109. JARRY U, Bostoen M, Archambeau J, Pineau R, et al
    Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
    PLoS One. 2024;19:e0304914.
    PubMed     Abstract available


  110. WANG C, Zhu X, Zheng M, Chen Y, et al
    Pan-cancer analysis of PSCA that is associated with immune infiltration and affects patient prognosis.
    PLoS One. 2024;19:e0298469.
    PubMed     Abstract available


  111. WANG B, Wang J, Sun T, Ding Y, et al
    Lu's approach for video-assisted thoracoscopic surgery.
    PLoS One. 2024;19:e0300632.
    PubMed     Abstract available


  112. GONG S, Li G, Li D, Liu Y, et al
    The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases.
    PLoS One. 2024;19:e0305670.
    PubMed     Abstract available



  113. Correction: Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter.
    PLoS One. 2024;19:e0306665.
    PubMed     Abstract available


  114. USHER-SMITH JA, Masson G, Godoy A, Burge SW, et al
    Acceptability of adding a non-contrast abdominal CT scan to screen for kidney cancer and other abdominal pathology within a community-based CT screening programme for lung cancer: A qualitative study.
    PLoS One. 2024;19:e0300313.
    PubMed     Abstract available


  115. PARK J, Rho MJ, Moon MH
    Enhanced deep learning model for precise nodule localization and recurrence risk prediction following curative-intent surgery for lung cancer.
    PLoS One. 2024;19:e0300442.
    PubMed     Abstract available


  116. LOTFI F, Rashidian H, Hadji M, Mohebbi E, et al
    Exposure to second-hand smoke and risk of lung cancer among Iranian population: A multicenter case-control study.
    PLoS One. 2024;19:e0306517.
    PubMed     Abstract available


  117. HAO H, Maeda Y, Fukazawa T, Yamatsuji T, et al
    Correction: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer.
    PLoS One. 2024;19:e0307052.
    PubMed     Abstract available


  118. VAN DEN BOSSCHE J, De Laere M, Deschepper K, Germonpre P, et al
    Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study.
    PLoS One. 2024;19:e0307204.
    PubMed     Abstract available


  119. ARMIJO N, Salas C, Espinoza N, Espinoza M, et al
    Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system.
    PLoS One. 2024;19:e0307473.
    PubMed     Abstract available


  120. CHEN XP, He SX, Chen MY, Chen FB, et al
    Meta-analysis of the accuracy for RASSF1A methylation in bronchial aspirates for the diagnosis of lung cancer.
    PLoS One. 2024;19:e0299447.
    PubMed     Abstract available


  121. SIL BK, Jamiruddin MR, Paul PK, Aekwattanaphol N, et al
    Ascorbic acid as serine protease inhibitor in lung cancer cell line and human serum albumin.
    PLoS One. 2024;19:e0303706.
    PubMed     Abstract available


  122. LIANG Y, Maeda O, Kondo C, Nishida K, et al
    Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.
    PLoS One. 2024;19:e0307580.
    PubMed     Abstract available


  123. MATSUMOTO H, Fukushima T, Kobayashi N, Higashino Y, et al
    High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse.
    PLoS One. 2024;19:e0299760.
    PubMed     Abstract available


  124. HUMMELINK K, van der Noort V, Muller M, Schouten RD, et al
    Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
    PLoS One. 2024;19:e0293707.
    PubMed     Abstract available


  125. KOUHMAREH K, Martin E, Finlay D, Bhadada A, et al
    Capture of circulating metastatic cancer cell clusters from lung cancer patients can reveal unique genomic profiles and potential anti-metastatic molecular targets: A proof-of-concept study.
    PLoS One. 2024;19:e0306450.
    PubMed     Abstract available


  126. SCHOUTEN RD, Schouten I, Schuurbiers MMF, van der Noort V, et al
    Optimising primary molecular profiling in non-small cell lung cancer.
    PLoS One. 2024;19:e0290939.
    PubMed     Abstract available


  127. KISS N, Ugalde A, Prado CM, Denehy L, et al
    Living with low muscle mass and its impact throughout curative treatment for lung cancer: A qualitative study.
    PLoS One. 2024;19:e0304003.
    PubMed     Abstract available


  128. PETERS HA, Weiss D, Boschheidgen M, Mamlins E, et al
    Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
    PLoS One. 2024;19:e0307998.
    PubMed     Abstract available


  129. SAJJADI SF, Salehi N, Sadeghi M
    Comprehensive integrated single-cell RNA sequencing analysis of brain metastasis and glioma microenvironment: Contrasting heterogeneity landscapes.
    PLoS One. 2024;19:e0306220.
    PubMed     Abstract available


  130. ITO M, Koido S, Iwamoto T, Morimoto S, et al
    Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors.
    PLoS One. 2024;19:e0308330.
    PubMed     Abstract available


  131. SARAJI A, Wulf K, Stegmann-Frehse J, Kang D, et al
    Comprehensive transcriptomic analysis of prostate cancer lung metastases.
    PLoS One. 2024;19:e0306525.
    PubMed     Abstract available


  132. ANANDAKRISHNAN R, Shahidi R, Dai A, Antony V, et al
    An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations.
    PLoS One. 2024;19:e0307232.
    PubMed     Abstract available


  133. MA Y, Li Z, Li D, Zheng B, et al
    G0 arrest gene patterns to predict the prognosis and drug sensitivity of patients with lung adenocarcinoma.
    PLoS One. 2024;19:e0309076.
    PubMed     Abstract available


  134. KILDAHL-ANDERSEN A, Hofstad EF, Solberg OV, Sorger H, et al
    Navigated ultrasound bronchoscopy with integrated positron emission tomography-A human feasibility study.
    PLoS One. 2024;19:e0305785.
    PubMed     Abstract available


  135. YU SC, Huang JY, Cheng YF, Cheng CY, et al
    Prognostic factors in clinical stage IIIA small cell lung cancer: An analysis of a population-based cancer registry in Taiwan.
    PLoS One. 2024;19:e0297399.
    PubMed     Abstract available


  136. LAI GS, Chen CS, Cheng JC, Li JR, et al
    Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients.
    PLoS One. 2024;19:e0309941.
    PubMed     Abstract available


  137. LIN L, Deng L, Bao Y
    Identifying crucial lncRNAs and mRNAs in hypoxia-induced A549 lung cancer cells and investigating their underlying mechanisms via high-throughput sequencing.
    PLoS One. 2024;19:e0307954.
    PubMed     Abstract available



  138. Correction: The efficacy of machine learning models in lung cancer risk prediction with explainability.
    PLoS One. 2024;19:e0310604.
    PubMed     Abstract available


  139. PIRES DC, Arueira Chaves L, Dantas Cardoso CH, Faria LV, et al
    Effects of low dose computed tomography (LDCT) on lung cancer screening on incidence and mortality in regions with high tuberculosis prevalence: A systematic review.
    PLoS One. 2024;19:e0308106.
    PubMed     Abstract available


  140. WU X, Li W, Chen Y
    Differences in the risk association of TERT-CLPTM1L rs4975616 (A>G) with lung cancer between Caucasian and Asian populations: A meta-analysis.
    PLoS One. 2024;19:e0309747.
    PubMed     Abstract available


  141. FANIZZI A, Fadda F, Maddalo M, Saponaro S, et al
    Developing an ensemble machine learning study: Insights from a multi-center proof-of-concept study.
    PLoS One. 2024;19:e0303217.
    PubMed     Abstract available


  142. GEUBBELMANS M, Claes J, Nijsten K, Gervois P, et al
    Optimization of whole slide imaging scan settings for computer vision using human lung cancer tissue.
    PLoS One. 2024;19:e0309740.
    PubMed     Abstract available


  143. KIM T, Choe J, Shin SH, Jeong BH, et al
    Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.
    PLoS One. 2024;19:e0310079.
    PubMed     Abstract available


  144. JAIN R, Singh P, Abdelkader M, Boulila W, et al
    Efficient lung cancer detection using computational intelligence and ensemble learning.
    PLoS One. 2024;19:e0310882.
    PubMed     Abstract available


  145. DJERIDI Z, Ghouar A, Boulares H, Bouye M, et al
    Applications of the prediction of satisfaction design for monitoring single-arm phase II trials.
    PLoS One. 2024;19:e0305814.
    PubMed     Abstract available


  146. HUANG H, Li L, Tong L, Luo H, et al
    Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
    PLoS One. 2024;19:e0310808.
    PubMed     Abstract available


  147. XIE J, He Y, Che S, Zhao W, et al
    Differential diagnosis of benign and lung adenocarcinoma presenting as larger solid nodules and masses based on multiscale CT radiomics.
    PLoS One. 2024;19:e0309033.
    PubMed     Abstract available


  148. NAGAMINE H, Yashiro M, Mizutani M, Sugimoto A, et al
    Insulin-like growth factor 1 receptor expression correlates with programmed death ligand 1 expression and poor survival in non-small cell lung cancer.
    PLoS One. 2024;19:e0297397.
    PubMed     Abstract available


  149. STOVERUD KH, Bouget D, Pedersen A, Leira HO, et al
    AeroPath: An airway segmentation benchmark dataset with challenging pathology and baseline method.
    PLoS One. 2024;19:e0311416.
    PubMed     Abstract available


  150. NDUAGUBA SO, Kelly KM
    Multilevel factors associated with delays in screening, diagnosis, and treatment for lung cancer-A mixed methods systematic review protocol.
    PLoS One. 2024;19:e0309196.
    PubMed     Abstract available


  151. PENG J, Xu H, Liu Q
    Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    PLoS One. 2024;19:e0312133.
    PubMed     Abstract available


  152. CHEN H, Hu XB, Zhou J, He CY, et al
    Association of chronic obstructive pulmonary disease with risk of lung cancer in individuals aged 40 years and older: A cross-sectional study based on NHANES 2013-2018.
    PLoS One. 2024;19:e0311537.
    PubMed     Abstract available


  153. GREGORY MD, Ofosu-Asante K, Lazarte JMS, Puente PE, et al
    Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces apoptosis.
    PLoS One. 2024;19:e0312563.
    PubMed     Abstract available


  154. MAHJABEEN A, Hasan MZ, Rahman MT, Islam MA, et al
    Genetic insights into the connection between pulmonary TB and non-communicable diseases: An integrated analysis of shared genes and potential treatment targets.
    PLoS One. 2024;19:e0312072.
    PubMed     Abstract available


  155. LV Z, Liu P, Yang Y, Ji J, et al
    (-)-Epicatechin regulates endoplasmic reticulum stress and promotes ferroptosis in lung cancer cells via the PERK/eIF2alpha/ATF4 signaling pathway.
    PLoS One. 2024;19:e0313010.
    PubMed     Abstract available


  156. SUZUKI S, Yashiro M, Izumi N, Tsukioka T, et al
    Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT.
    PLoS One. 2024;19:e0312846.
    PubMed     Abstract available


  157. PAVEL MA, Islam R, Babor SB, Mehadi R, et al
    Non-small cell lung cancer detection through knowledge distillation approach with teaching assistant.
    PLoS One. 2024;19:e0306441.
    PubMed     Abstract available


  158. YANG Y, Li J, Wang Y, Luo L, et al
    Prognostic value of the systemic immune-inflammation index in lung cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    PLoS One. 2024;19:e0312605.
    PubMed     Abstract available



  159. Retraction: Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer.
    PLoS One. 2024;19:e0314046.
    PubMed    


  160. LIAO Y, Zhou Y, Zhou X, Chen J, et al
    Gastroesophageal reflux disease and risk of incident lung cancer: A large prospective cohort study in UK Biobank.
    PLoS One. 2024;19:e0311758.
    PubMed     Abstract available


  161. CAI S, Yang W, Luo H, Li Z, et al
    Clinical features and prognostic factors of IV combined small cell lung cancer: A propensity score matching analysis.
    PLoS One. 2024;19:e0313221.
    PubMed     Abstract available


  162. SLOMKA J, Berthou H, Mansuet-Lupo A, Blons H, et al
    Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.
    PLoS One. 2024;19:e0307161.
    PubMed     Abstract available


  163. DONG Y, Li S, Che G
    Is it safe and feasible to use multi-lateral-pores drainage strategy after video-assisted thoracoscopic surgery?
    PLoS One. 2024;19:e0313176.
    PubMed     Abstract available


  164. BONERT M, Schittenhelm J, Begum H, Lu JQ, et al
    Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.
    PLoS One. 2024;19:e0314205.
    PubMed     Abstract available


  165. ZHANG E, Feng X, Liu F, Zhang P, et al
    Correction: Roles of PI3K/Akt and c-Jun Signaling Pathways in Human Papillomavirus Type 16 Oncoprotein-Induced HIF-1alpha, VEGF, and IL-8 Expression and In Vitro Angiogenesis in Non-Small Cell Lung Cancer Cells.
    PLoS One. 2024;19:e0314378.
    PubMed     Abstract available


  166. YADAV DP, Sharma B, Webber JL, Mehbodniya A, et al
    EDTNet: A spatial aware attention-based transformer for the pulmonary nodule segmentation.
    PLoS One. 2024;19:e0311080.
    PubMed     Abstract available


  167. GUIBIN D, Xiaolan S, Wei Z, Xiaoli L, et al
    Prediction of iodine-125 seed implantation efficacy in lung cancer using an enhanced CT-based nomogram model.
    PLoS One. 2024;19:e0313570.
    PubMed     Abstract available


  168. WANG S, Yan H, Wen J, Zhou Z, et al
    Risk factors for conversion to thoracotomy in patients with lung cancer undergoing video-assisted thoracoscopic surgery: A meta-analysis.
    PLoS One. 2024;19:e0313236.
    PubMed     Abstract available


  169. ARUNACHALAM A, Sura S, Murphy J, Conkling P, et al
    Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer.
    PLoS One. 2024;19:e0314156.
    PubMed     Abstract available


  170. JIANG HN, Zeng B, Zhang Y, Daskoulidou N, et al
    Correction: Involvement of TRPC Channels in Lung Cancer Cell Differentiation and the Correlation Analysis in Human Non-Small Cell Lung Cancer.
    PLoS One. 2024;19:e0315242.
    PubMed     Abstract available


  171. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    PLoS One. 2024;19:e0315252.
    PubMed     Abstract available


  172. JALILIAN H, Heydari S, Javanshir E, Jamebozorgi K, et al
    Hospitalization costs and out-of-pocket (OOP) payment in lung cancer patients in Iran: Health Sector Evolution Plan (HSEP) has reduced OOP payments and improved financial protection.
    PLoS One. 2024;19:e0297934.
    PubMed     Abstract available


  173. CHATWICHIEN J, Semakul N, Yimklan S, Suwanwong N, et al
    Lutein derived from Xenostegia tridentata exhibits anticancer activities against A549 lung cancer cells via hyaluronidase inhibition.
    PLoS One. 2024;19:e0315570.
    PubMed     Abstract available


  174. YUAN S, Ou W, Mi X, Hou J, et al
    Enhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways.
    PLoS One. 2024;19:e0310825.
    PubMed     Abstract available


  175. KLIMONTOVA M, Zhang H, Campos-Laborie F, Webster N, et al
    THUMPD3 regulates alternative splicing of ECM transcripts in human lung cancer cells and promotes proliferation and migration.
    PLoS One. 2024;19:e0314655.
    PubMed     Abstract available


  176. HANAOKA S, Nomura Y, Hayashi N, Sato I, et al
    Deep generative abnormal lesion emphasization validated by nine radiologists and 1000 chest X-rays with lung nodules.
    PLoS One. 2024;19:e0315646.
    PubMed     Abstract available


  177. ZHANG H, Liu S, Zhang J, Wang Y, et al
    CD47 expression in non-small cell lung cancer and its relationship with tumor-associated macrophage infiltration.
    PLoS One. 2024;19:e0314228.
    PubMed     Abstract available


  178. ROMASZKO-WOJTOWICZ A, Doboszynska A, Piechnik A, Kuziemski K, et al
    Impact of the COVID-19 pandemic on lung cancer diagnosis in northern Poland-addressing the COVID-19 debt.
    PLoS One. 2024;19:e0316261.
    PubMed     Abstract available


  179. SAIT ARW, AlBalawi E, Nagaraj R
    Ensemble learning driven Kolmogorov-Arnold Networks-based Lung Cancer classification.
    PLoS One. 2024;19:e0313386.
    PubMed     Abstract available


  180. SALAZAR P, Cheung P, Ganeshan B, Oikonomou A, et al
    Predefined and data-driven CT radiomics predict recurrence-free and overall survival in patients with pulmonary metastases treated with stereotactic body radiotherapy.
    PLoS One. 2024;19:e0311910.
    PubMed     Abstract available


  181. SAETANG M, Kunapaisal T, Wasinwong W, Boonthum P, et al
    Predictors associated with Clavien-Dindo complications in lung cancer surgery: A retrospective cohort study.
    PLoS One. 2024;19:e0316214.
    PubMed     Abstract available


  182. DU L, Ren W, Liu L, Zhu H, et al
    SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway.
    PLoS One. 2024;19:e0316432.
    PubMed     Abstract available


    January 2023
  183. LIU Y
    Identification and comprehensive analysis of super-enhancer related genes involved in epithelial-to-mesenchymal transition in lung adenocarcinoma.
    PLoS One. 2023;18:e0291088.
    PubMed     Abstract available


  184. ZHOU D, Zhai X, Zhang R
    Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
    PLoS One. 2023;18:e0291461.
    PubMed     Abstract available


  185. DAEI SORKHABI A, Fazlollahi A, Sarkesh A, Aletaha R, et al
    Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials.
    PLoS One. 2023;18:e0291044.
    PubMed     Abstract available


  186. WU M, Liu S, Wang C, Wu Y, et al
    Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0291178.
    PubMed     Abstract available


  187. LIU Y, Yan M
    Trends in all causes and cause specific mortality attributable to ambient particulate matter pollution in China from 1990 to 2019: A secondary data analysis study.
    PLoS One. 2023;18:e0291262.
    PubMed     Abstract available



  188. Retraction: Frondoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and Metastasis.
    PLoS One. 2023;18:e0291478.
    PubMed    


  189. FUJIKAWA K, Saito T, Kurose K, Kojima T, et al
    Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
    PLoS One. 2023;18:e0291772.
    PubMed     Abstract available


  190. LEROY K, Audigier Valette C, Alexandre J, Boussemart L, et al
    Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
    PLoS One. 2023;18:e0291495.
    PubMed     Abstract available


  191. BINGHAM SL, Small S, Semple CJ
    A qualitative evaluation of a multi-modal cancer prehabilitation programme for colorectal, head and neck and lung cancers patients.
    PLoS One. 2023;18:e0277589.
    PubMed     Abstract available


  192. IKEMOTO S, Sakurai F, Tokuoka S, Yamashita T, et al
    Novel conditionally replicating adenovirus-mediated efficient detection of circulating tumor cells in lung cancer patients.
    PLoS One. 2023;18:e0286323.
    PubMed     Abstract available


  193. WESTEEL V, Schuette W, Urban T, Radonjic D, et al
    Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
    PLoS One. 2023;18:e0292307.
    PubMed     Abstract available


  194. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2023;18:e0294382.
    PubMed     Abstract available


  195. MAKRAKIS D, Rounis K, Tsigkas AP, Georgiou A, et al
    Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    PLoS One. 2023;18:e0294384.
    PubMed     Abstract available


  196. PENG B, Ling X, Huang T, Wan J, et al
    HSP70 via HIF-1 alpha SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation.
    PLoS One. 2023;18:e0294263.
    PubMed     Abstract available


  197. LIMBU S, McCloskey KE
    Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.
    PLoS One. 2023;18:e0294171.
    PubMed     Abstract available


  198. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    PubMed     Abstract available


  199. NIBID L, Greco C, Cordelli E, Sabarese G, et al
    Deep pathomics: A new image-based tool for predicting response to treatment in stage III non-small cell lung cancer.
    PLoS One. 2023;18:e0294259.
    PubMed     Abstract available


  200. ARBEE-KALIDAS N, Moutlana HJ, Moodley Y, Kebalepile MM, et al
    The association between cardiopulmonary exercise testing and postoperative outcomes in patients with lung cancer undergoing lung resection surgery: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0295430.
    PubMed     Abstract available


  201. NEMLANDER E, Rosenblad A, Abedi E, Ekman S, et al
    Correction: Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers.
    PLoS One. 2023;18:e0295780.
    PubMed     Abstract available


  202. WANG J, Wang H, Xu J, Song Q, et al
    Identification of protein signatures for lung cancer subtypes based on BPSO method.
    PLoS One. 2023;18:e0294243.
    PubMed     Abstract available


  203. WU YY, Shen WB, Li JW, Liu MY, et al
    Targeted metabolomics reveals the association between central carbon metabolism and pulmonary nodules.
    PLoS One. 2023;18:e0295276.
    PubMed     Abstract available



  204. Retraction: Restoration of Mal overcomes the defects of apoptosis in lung cancer cells.
    PLoS One. 2023;18:e0296552.
    PubMed    



  205. Correction: Nicotine Promotes Tumor Growth and Metastasis in Mouse Models of Lung Cancer.
    PLoS One. 2023;18:e0296477.
    PubMed     Abstract available


  206. TIAN W, Guo Q, Fu D, Ma X, et al
    Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials.
    PLoS One. 2023;18:e0295745.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.